MeiraGTx (MGTX) Expected to Announce Quarterly Earnings on Thursday

MeiraGTx (NASDAQ:MGTX - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect MeiraGTx to post earnings of ($0.38) per share and revenue of $4.44 million for the quarter.

MeiraGTx (NASDAQ:MGTX - Get Free Report) last posted its earnings results on Thursday, March 13th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.02). The business had revenue of $21.39 million during the quarter, compared to analyst estimates of $1.50 million. MeiraGTx had a negative return on equity of 146.38% and a negative net margin of 633.05%. On average, analysts expect MeiraGTx to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MeiraGTx Stock Down 11.0 %

Shares of MeiraGTx stock traded down $0.80 on Monday, hitting $6.45. The company had a trading volume of 1,648,207 shares, compared to its average volume of 335,071. MeiraGTx has a 1 year low of $3.85 and a 1 year high of $8.75. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.34 and a current ratio of 2.34. The stock has a 50 day moving average of $6.54 and a 200-day moving average of $6.38. The stock has a market capitalization of $515.68 million, a price-to-earnings ratio of -5.33, a P/E/G ratio of 0.37 and a beta of 1.30.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Royal Bank of Canada raised their price objective on MeiraGTx from $11.00 to $13.00 and gave the company an "outperform" rating in a research note on Monday, March 17th. Chardan Capital reaffirmed a "buy" rating and issued a $36.00 price objective on shares of MeiraGTx in a research report on Monday, February 24th.

Insider Buying and Selling

In related news, CEO Alexandria Forbes sold 47,500 shares of the firm's stock in a transaction dated Tuesday, April 8th. The shares were sold at an average price of $5.34, for a total transaction of $253,650.00. Following the completion of the sale, the chief executive officer now owns 1,408,983 shares in the company, valued at approximately $7,523,969.22. This trade represents a 3.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Richard Giroux sold 24,000 shares of the firm's stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $6.00, for a total transaction of $144,000.00. Following the sale, the chief financial officer now owns 882,494 shares of the company's stock, valued at approximately $5,294,964. The trade was a 2.65 % decrease in their position. The disclosure for this sale can be found here. 8.40% of the stock is currently owned by corporate insiders.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.